Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by EndoHypoton Nov 18, 2020 3:32pm
101 Views
Post# 31924294

RE:Stony Brook PMX COVID 19 study- and two EAA studies

RE:Stony Brook PMX COVID 19 study- and two EAA studiesThis is why Stony Brook has multiple studies researching the connection between Endotoxin, Covid, and Kidney damage.


Fears Covid may leave thousands in UK with severe kidney disease


Tens of thousands of people may require kidney dialysis or transplants because of coronavirus, according to experts who warn the long-term effects of Covid are causing an “epidemic in primary care”.

Up to 90% of coronavirus patients admitted to hospital may still experience symptoms two to three months later – from breathlessness to joint pain, fatigue and chest pain – scientists told the Lords science and technology committee on Tuesday.

Donal O’Donoghue, a consultant renal physician at Salford Royal NHS trust, said damage to the kidneys was of major concern. It is believed the virus may attack the organ directly, he said, while the kidneys could also be injured by body-wide inflammation caused by the virus.

“Normally we see maybe 20% of people that go on to intensive care unit need to have a form of dialysis. During Covid it was up to 40% and 85% of people had some degree of kidney injury,” he said. “No doubt that is happening out in the community as well, probably to a lesser extent.”

O’Donoghue said it was unknown how many of these patients would go on to develop more severe kidney disease, but that the figures could be high. “It could easily be tens of thousands more people requiring dialysis [or] transplantation,he said, adding that in a normal year about 6,500 people were accepted on to dialysis and transplant programmes.

Chris Brightling, professor of respiratory medicine of the University of Leicester who is leading the Phosp-Covid study into the long-term effects of the disease, said research in Italy had given further clues as to the scale of the virus’s lasting effects.

“This suggested even when you are looking at people who have been hospitalised two to three months later, after discharge, then only about 10-15% of people have no persistent symptoms,” he said.

 

Brightling said pilot data from whole body scans of 50 patients who are part of the Phos-Covid and C-MORE studies were revealing the wider physiological impact of Covid-19.

“[These] are showing end-organ damage in the kidneys, in the liver, in the lungs and in the heart, and less so in the brain. This is affecting over a third of the individuals at the two month point,” he said. “We are really getting a lot of clues that there are things that are happening across multiple organs from a disease that initially starts as a respiratory infection.”


Read more.
https://www.theguardian.com/world/2020/sep/15/fears-covid-may-leave-thousands-in-uk-with-severe-kidney-disease-long-term-effects-coronavirus

 


 

<< Previous
Bullboard Posts
Next >>